Sonia Morgan-Linnell

Featured in: Favicon

Articles

66 Prospective study shows 31-gene expression profile test stratifies recurrence-free survival and improves American Joint Committee on Cancer (AJCC) risk prediction in stage IB-IIA cutaneous melanoma | Journal for ImmunoTherapy of Cancer

Nov 1, 2024 | jitc.bmj.com | Etan Marks |Robert Cook |Sonia Morgan-Linnell |Joseph Gadzia

Abstract Background Currently, FDA-approved adjuvant immunotherapies are not approved for patients with stage IB–IIA cutaneous melanoma (CM), and this group is not recommended for asymptomatic surveillance imaging.1 However, patients with stage IB-IIA CM have up to 20–38% recurrence rates and account for approximately one-quarter of all patients with CM.2 3 Thus, additional methods to identify which patients in this group are at the highest risk for recurrence are needed so that clinicians...
The i31-GEP for sentinel lymph node (SLN) biopsy outperforms the MSKCC nomogram in predicting the risk of having a positive SLN in patients with cutaneous melanoma | SKIN The Journal of Cutaneous Medicine

May 20, 2023 | jofskin.org | Danny Zakria |Sonia Morgan-Linnell |Castle Biosciences |Nicholas D. Brownstone

Main Article Content Keywords 31-GEP, cutaneous melanoma, nomogram, sentinel lymph node biopsy References 1. National Comprehensive Cancer Guidelines, v2, 2022. 2.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.